Arbor Partners with Acuitas for Lipid Nanoparticle Delivery System for Use in Rare Liver Diseases
August 25, 2022
Gene editing biotech Arbor Biotechnologies said it has entered into an agreement with Acuitas Therapeutics, a developer of lipid nanoparticles in which the companies will combine the optimized delivery of Acuitas’ validated LNP technology with Arbor’s differentiated, proprietary CRISPR gene editing technology designed for use in vivo in patients with rare liver diseases.
Arbor’s proprietary discovery engine is focused on discovering genetic editing capabilities spanning knockdowns to whole gene insertions to generate an extensive toolbox of proprietary genomic editors.
“We are building a robust, proprietary portfolio of genomic medicines, beginning with severe liver diseases, for which LNPs are known to provide an optimal delivery approach with their ability to efficiently target hepatocytes, limit off target toxicity and have minimal immunogenicity. We are looking forward to working with Acuitas, a leading global developer of clinically validated LNP technology,” said Devyn Smith, CEO of Arbor Biotechnologies. “Importantly, we believe this partnership accelerates our path to the clinic, with an ability to leverage established and scalable manufacturing.”
Vancouver-based Acuitas Therapeutics specializes in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles.
Author: Rare Daily Staff
Sign up for updates straight to your inbox.